<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00075426</url>
  </required_header>
  <id_info>
    <org_study_id>02-402</org_study_id>
    <secondary_id>CDR0000346366</secondary_id>
    <nct_id>NCT00075426</nct_id>
  </id_info>
  <brief_title>Arsenic Trioxide in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Pilot Phase II Protocol Of Arsenic Trioxide (Trisenox) In Subjects With Advanced Non-Small Cell Carcinoma Of The Lung</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Medical Branch, Galveston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Medical Branch, Galveston</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide, use different ways to stop&#xD;
      tumor cells from dividing so they stop growing or die.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well arsenic trioxide works in treating patients&#xD;
      with locally advanced or metastatic non-small cell lung cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the safety and activity of arsenic trioxide in patients with locally advanced&#xD;
           or metastatic non-small cell lung cancer.&#xD;
&#xD;
        -  Determine the qualitative and quantitative toxic effects of this drug in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the response, in terms of objective tumor response and response duration, in&#xD;
           patients treated with this drug.&#xD;
&#xD;
        -  Determine the patterns of failure and survival in patients treated with this drug.&#xD;
&#xD;
      OUTLINE: This is a pilot study.&#xD;
&#xD;
      Patients receive arsenic trioxide IV over 1-2 hours on days 1-5 of week 1 and on days 1 and 5&#xD;
      of weeks 2-8 (course 1 only). Beginning with course 2 and for all subsequent courses,&#xD;
      patients receive arsenic trioxide on days 1 and 5 of weeks 1-8. Treatment repeats every 8&#xD;
      weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.&#xD;
      Patients achieving complete response (CR) receive 1 additional course of therapy beyond CR.&#xD;
      Patients achieving CR due to local consolidative therapy (surgery or radiotherapy) receive 2&#xD;
      additional courses of therapy beyond CR.&#xD;
&#xD;
      Patients are followed for 1 month, every 3 months for 2 years, every 6 months for 3 years,&#xD;
      and then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 14-30 patients will be accrued for this study within 9-18&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2002</start_date>
  <completion_date type="Actual">July 2005</completion_date>
  <primary_completion_date type="Actual">July 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>arsenic trioxide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed non-small cell lung cancer (NSCLC), meeting criteria for 1 of&#xD;
             the following:&#xD;
&#xD;
               -  Locally advanced disease not amenable to radiotherapy or surgery&#xD;
&#xD;
               -  Metastatic disease&#xD;
&#xD;
          -  Received at least 1 course of platinum-based (e.g., cisplatin or carboplatin)&#xD;
             chemotherapy&#xD;
&#xD;
          -  No uncontrolled central nervous system (CNS) metastases&#xD;
&#xD;
          -  Ineligible for higher priority treatment protocols&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) 0-1 OR&#xD;
&#xD;
          -  Zubrod Scale 0-1 OR&#xD;
&#xD;
          -  South West Oncology Group (SWOG) 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count greater than 1,500/mm^3&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times normal&#xD;
&#xD;
          -  Serum glutamate oxaloacetate transaminase (SGOT) and Serum glutamate pyruvate&#xD;
             transaminase (SGPT) no greater than 3 times normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
          -  Calcium no greater than 12 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No uncontrolled, clinically significant dysrhythmia&#xD;
&#xD;
          -  Cardiac ejection fraction greater than 50%&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Electrolytes (including magnesium) normal&#xD;
&#xD;
          -  No other malignancy within the past 5 years except nonmelanoma skin cancer or&#xD;
             carcinoma in situ of the cervix&#xD;
&#xD;
          -  No prior or ongoing peripheral neuropathy grade 2 or greater&#xD;
&#xD;
          -  No other medical condition that would preclude study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  No concurrent cytokine therapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No more than 2 prior chemotherapy regimens for NSCLC&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 2 weeks since prior radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to an indicator lesion unless there is objective evidence of&#xD;
             tumor growth in that lesion&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
               -  Concurrent palliative or emergent radiotherapy allowed&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  More than 2 weeks since prior surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 4 weeks since prior antineoplastic agents for non-malignant conditions (e.g.,&#xD;
             methotrexate for rheumatoid arthritis)&#xD;
&#xD;
          -  No concurrent antineoplastic agents for non-malignant conditions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dennie V. Jones, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Medical Branch</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555-0209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>January 9, 2004</study_first_submitted>
  <study_first_submitted_qc>January 11, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2004</study_first_posted>
  <last_update_submitted>February 11, 2013</last_update_submitted>
  <last_update_submitted_qc>February 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IIIA non-small cell lung cancer</keyword>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arsenic Trioxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

